- Home
- INSM vs CNP Comparison
INSM vs CNP Comparison
Compare INSM & CNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- CNP
- Stock Information
- Founded
- INSM 1988
- CNP 1866
- Country
- INSM United States
- CNP United States
- Employees
- INSM N/A
- CNP N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- CNP Electric Utilities: Central
- Sector
- INSM Health Care
- CNP Utilities
- Exchange
- INSM Nasdaq
- CNP Nasdaq
- Market Cap
- INSM 29.0B
- CNP 25.7B
- IPO Year
- INSM 2000
- CNP N/A
- Fundamental
- Price
- INSM $182.69
- CNP $38.69
- Analyst Decision
- INSM Strong Buy
- CNP Buy
- Analyst Count
- INSM 19
- CNP 12
- Target Price
- INSM $171.12
- CNP $41.29
- AVG Volume (30 Days)
- INSM 2.1M
- CNP 4.8M
- Earning Date
- INSM 10-30-2025
- CNP 10-23-2025
- Dividend Yield
- INSM N/A
- CNP 2.27%
- EPS Growth
- INSM N/A
- CNP 5.29
- EPS
- INSM N/A
- CNP 1.58
- Revenue
- INSM $447,022,000.00
- CNP $9,114,000,000.00
- Revenue This Year
- INSM $40.09
- CNP $6.80
- Revenue Next Year
- INSM $129.64
- CNP $4.38
- P/E Ratio
- INSM N/A
- CNP $24.51
- Revenue Growth
- INSM 30.34
- CNP 6.43
- 52 Week Low
- INSM $60.40
- CNP $28.57
- 52 Week High
- INSM $197.08
- CNP $40.50
- Technical
- Relative Strength Index (RSI)
- INSM 67.29
- CNP 45.39
- Support Level
- INSM $178.76
- CNP $37.81
- Resistance Level
- INSM $197.08
- CNP $39.90
- Average True Range (ATR)
- INSM 7.01
- CNP 0.59
- MACD
- INSM 1.60
- CNP -0.20
- Stochastic Oscillator
- INSM 65.96
- CNP 32.84
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About CNP CenterPoint Energy Inc (Holding Co)
CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio. The company has natural gas distribution systems serving approximately 4 million customers.